letrozole / Generic mfg. - LARVOL DELTA

Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026). (PubMed, J Clin Oncol) - "Ribociclib plus letrozole met the primary end point, achieving meaningful response rates and durable disease control in recurrent LGSOC. The safety profile was consistent with prior CDK4/6 inhibitor studies. This combination represents a therapeutic option in this rare and genomically distinct subtype."

Journal • P2 data • Breast Cancer • Fallopian Tube Cancer • Hematological Disorders • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Low Grade Serous Carcinoma • Neutropenia • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor • ER

Neoadjuvant Abemaciclib plus Letrozole vs. Chemotherapy in patients with HR+/HER2- Highly Proliferative Breast Cancer. (PubMed, Clin Cancer Res) - "CARABELA trial results suggest that 12 months of letrozole/abemaciclib may not offer similar efficacy to that of chemotherapy in achieving RCB 0-I. However, in less proliferative tumors (RS <26 or Ki-67 <30%), outcomes were comparable, suggesting that letrozole/abemaciclib could replace (neo)adjuvant chemotherapy in selected patients."

Journal • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Real-world Pharmacovigilance Study of Drug-induced Diabetes Insipidus from the FAERS Database. (PubMed, Endocr Connect) - "Lithium (n = 114, Information Component at the 95% lower credibility interval [IC025] = 6.12) and dexmedetomidine (n = 105, IC025 = 6.79) were identified as the most frequently reported drugs and showed the strongest association with DI. Several drugs, such as aripiprazole, letrozole, tigecycline, and dapagliflozin, were found to have unexpected potential associations with DI. This study provides a comprehensive overview of drug-induced DI based on real-world data. It highlights the importance of monitoring patients for DI when using certain medications, particularly high-risk nervous system drugs and antineoplastic agents."

Adverse events • Journal • Real-world evidence • Metabolic Disorders • Oncology

Combination metformin and liraglutide in PCOS: clinical efficacy in women and preclinical insights from gut microbiome modulation in rats. (PubMed, Front Endocrinol (Lausanne)) - "In a separate animal study, female Sprague-Dawley rats were divided into five groups: (1) PCOS model group (letrozole 1 mg/kg orally); (2) MET group (letrozole + metformin 200 mg/kg orally); (3) LIRA group (letrozole + liraglutide 0.2 mg/kg subcutaneously); (4) COM group (letrozole + metformin + liraglutide at above doses); and (5) healthy controls (no treatment). Metformin combined with liraglutide significantly improved metabolic and endocrine characteristics in PCOS women. The associated amelioration of gut microbiota dysbiosis in PCOS rats suggests a potential mechanistic link, which warrants verification in future clinical studies."

Clinical • Journal • Preclinical • Gastrointestinal Disorder • Obesity • Polycystic Ovary Syndrome

BI14 Case series: exploring the link between psoriasis and cyclin-dependent kinase 4/6 inhibitors in breast cancer treatment. (PubMed, Br J Dermatol) - "She was initiated on palbociclib and letrozole treatment in April 2024...She was commenced on ribociclib and letrozole for relapsed metastatic liver disease in April 2023...Understanding the role of CDK4/6 inhibition and the link with psoriasis is important for optimizing therapeutic choices for patients with cancer with pre-existing or newly developed psoriasis. Given the increasing use of CDK4/6 inhibitors in cancer treatment, clinicians should be vigilant of the potential increased prevalence of psoriasis experienced in this patient cohort."

Journal • Breast Cancer • Dermatology • Dermatopathology • Hepatology • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Immunology • Oncology • Psoriasis • Solid Tumor • ER • HER-2 • IL17A • IL22

P021 A case of radiation-induced haemorrhagic bullous lichen sclerosus of the breast. (PubMed, Br J Dermatol) - "Her right breast ductal carcinoma, diagnosed 9 months prior, was treated with surgery, adjuvant letrozole and radiotherapy...Management options include topical and systemic corticosteroids, phototherapy and methotrexate (Hobbs L, Tiwari N. Hemorrhagic bullous lichen sclerosus of the breast: a rare complication of radiotherapy...To the best of our knowledge, this is the fifth reported case of RHBLS. Early recognition is crucial to alleviate concerns about breast cancer recurrence and to rule out vulval lichen sclerosus."

Journal • Breast Cancer • Cardiovascular • Coronary Artery Disease • Dermatology • Diabetes • Heart Failure • Hematological Disorders • Hypertension • Immunology • Metabolic Disorders • Oncology • Pain • Pruritus • Solid Tumor • Type 1 Diabetes Mellitus • IL4

Drug utilisation evaluation of oral anticancer therapy in a south indian cancer centre (ESMO Asia 2025) - "Among targeted therapies, Gefitinib, Osimertinib, Crizotinib, Afatinib, Lorlatinib, and Nilotinib demonstrated consumption of 30 DDDs per patient over 30 days. Lower consumptions were observed with Lenvatinib and Cabozantinib with 13.3 DDDs and 11.25 DDDs per patient respectively. In the hormonal therapy group, Letrozole, Tamoxifen, Bicalutamide, Anastrozole, Enzalutamide, and Exemestane were all prescribed in line with WHO standards (30 DDDs per patient), whereas Abiraterone exhibited lower consumption of 15 DDDs per patient. Prescribing patterns and consumption metrics were largely consistent with WHO criteria, indicating rational oral anticancer drug use. Prescribing patterns and consumption metrics were largely consistent with WHO criteria, indicating rational oral anticancer drug use. Dose deviations occurred, though reasons were unclear and may relate to adverse effects, indication-specific or patient factors, or economic constraints. Further research is warranted..."

Oncology • Oral Cancer

Clinical and prognostic characteristics of intravenous leiomyomatosis (ESMO Asia 2025) - "Uterine preservation and extent of tumor lesion were risk factors of for post-operative recurrence. Bilateral oophorectomy can not reduce the recurrent rate, ovarian preservation may be considered in younger patients to enhance quality of life."

Clinical • Gynecologic Cancers • Oncology • Solid Tumor

Molecular classification of breast cancer in Bhutan (ESMO Asia 2025) - "This analysis highlights the molecular heterogeneity of breast cancer in Bhutan, with a significant proportion of HER2+ and TNBC cases. The high rate of advanced-stage presentation underscores the need for earlier detection. The high mastectomy rate reflects the absence of radiotherapy in-country."

Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2

The potential effects of the synergistic interaction between ferulic acid and new generation CDK inhibitor anti-neoplastic drugs on breast cancer anti-tumour activity. (PubMed, Med Oncol) - "Ribociclib (Ribo) and Abemaciclib (Abe) are new-generation CDK inhibitors approved for use in breast cancer treatment. Some molecular mechanisms were elucidated by revealing the synergistic effect of FA combined with Ribo and/or Abe in both HR positive and HR negative breast cancer and its possible toxicity or protection on normal breast cells. The present findings suggest that FA is a viable candidate for adjuvant or neoadjuvant treatment in combination with Ribo and/or Abe, as an alternative to Letrozole or Fulvestrant, which have been associated with significant adverse effects in clinical settings."

Journal • Breast Cancer • Eye Cancer • Hormone Receptor Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Retinal Disorders • Retinoblastoma • Solid Tumor • ER

Updated results and an exploratory analysis of ESR1m circulating tumor DNA (ctDNA) dynamics from SERENA-6, a phase 3 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1 mutations (ESR1m) during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2- advanced breast cancer (ABC) (SABCS 2025) - "Methods SERENA-6, a randomized, double-blind, phase 3 trial, enrolled pts with HR+/HER2- ABC who had received ≥6 months of 1L AI (anastrozole/letrozole) + CDK4/6i (palbociclib/ribociclib/abemaciclib). No new safety signals were observed. These results further support an early switch to CAMI + CDK4/6i during 1L therapy to delay disease progression."

Circulating tumor DNA • Clinical • Metastases • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • CDK4 • ER • HER-2

Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - P1/2 | N=792 | Recruiting | Sponsor: Hoffmann-La Roche | N=580 ➔ 792 | Trial completion date: May 2028 ➔ Sep 2030 | Trial primary completion date: May 2028 ➔ Sep 2030

Enrollment change • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PD-L1 • PIK3CA

I- SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant vepdegestrant monotherapy or in combination with letrozole or abemaciclib in molecularly selected patients with stage 2/3 HR+ HER2-negative breast cancer (BC) (SABCS 2025) - "Six months of neoadjuvant vepdegestrant, alone or in combination with letrozole or abemaciclib, is feasible and demonstrates robust ER/PR degradation. Encouraging anti-tumor activity through reduction of Ki67 and MRI FTV, ctDNA clearance, and achievement of BCS was seen in pre- and postMN women. The neoadjuvant setting provides a rich platform to identify the dynamic range of response and non-response using a multi-modal approach and can be leveraged to inform future trial design and adjuvant therapy."

Clinical • Combination therapy • Monotherapy • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Emulation of the MONALEESA-2 Trial Using Specialty Oncology Electronic Health Records Databases (clinicaltrials.gov) - P=N/A | N=2495 | Active, not recruiting | Sponsor: Shirley Vichy Wang

New trial • Breast Cancer • Oncology • Solid Tumor

Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole (clinicaltrials.gov) - P=N/A | N=42 | Completed | Sponsor: Pfizer | N=28 ➔ 42

Enrollment change • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

CD8+ T cells in the tumor microenvironment modulate response to endocrine therapy in breast cancer. (PubMed, J Clin Invest) - "We analyzed pre- and on-treatment biopsies from patients with HR+ breast cancer treated with letrozole to induce estrogen deprivation (ED)...Finally, deletion combined with silencing of the CXCL11 receptors CXCR3 and CXCR7 in MCF7 cells impaired proliferation in response to exogenous CXCL11 and to co-culture with CD8+ T cells in estrogen-free conditions. These findings suggest that CD8+ T cell-associated CXCL11 in the TIME modulates the response of HR+ breast cancer cells to estrogen suppression."

Biomarker • Journal • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ACKR3 • CD8 • CXCL10 • CXCL11 • CXCL9 • CXCR3

Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies (clinicaltrials.gov) - P2 | N=35 | Active, not recruiting | Sponsor: Pfizer | Recruiting ➔ Active, not recruiting

Enrollment closed • Breast Cancer • Head and Neck Cancer • Oncology • Solid Tumor

Fertility Medications and Urticaria Subtypes: Real-World Comparative Study Analyzing Risks Among Clomiphene, GnRH Agonists, and Letrozole. (PubMed, Int J Dermatol) - No abstract available

Journal • Real-world evidence • Dermatology • Immunology • Urticaria

Lack of effects of S-equol-containing supplement on the pharmacokinetics of oral hormone therapy drugs for breast cancer. (PubMed, Cancer Chemother Pharmacol) - "S-equol-containing supplement has no clinically significant effects on the exposure of oral hormone therapy drugs for breast cancer. TRIAL REGISTRATION NUMBER AND DATE OF REGISTRATION: jRCTs031200084, August 13th, 2020."

Journal • PK/PD data • Breast Cancer • Musculoskeletal Diseases • Musculoskeletal Pain • Oncology • Pain • Solid Tumor

Hyperandrogenism associated deregulation of hippocampal adipokines may contribute to impaired memory function in mice. (PubMed, Brain Res) - "Thus, this study aimed to explore the expression of leptin, leptin receptor, adiponectin, adipoR1 and adipoR2 along with androgen receptor and estrogen receptors in the hippocampus of letrozole-induced hyperandrogenised mice...Thus, it can be suggested that hyperandrogenism may be associated with deregulation of adipokines and steroid signaling along with neuronal degeneration in the hippocampus, and might also be linked to behavioral issues in the hyperandrogenised conditions with declined in spatial working memory when assessed in Y-Maze test. Since, our study was aimed to explore the expression of above proteins and linking with cognitive impairment in the hyperandrogenised conditions, yet, it is speculative and requires further investigation with auxiliary behavioral tests."

IO biomarker • Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Depression • Mood Disorders • Psychiatry • AR • BCL2 • CASP3 • ER • LEP • LEPR

Aromatase inhibitors and medication-related osteonecrosis of the jaw: friends, foes, or bystanders? (PubMed, Crit Rev Oncol Hematol) - "Letrozole was the most frequently prescribed AI, followed by anastrozole and exemestane. MRONJ was reported in 43 studies, with 1,147 cases among 45,121 AI users (2.5% of AI users in the included samples), the majority of whom were concomitantly treated with zoledronic acid and/or denosumab...Data demonstrate the difficulty of disentangling the effects of AI from those of antiresorptive therapy in MRONJ pathogenesis. Future research should consider AI as potential confounders in analytical studies to clarify their independent contribution, if any, to observed MRONJ occurrences."

Journal • Review • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

ELEGANCE: Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia (clinicaltrials.gov) - P=N/A | N=2766 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Jul 2032 ➔ Dec 2032 | Initiation date: Jul 2025 ➔ Dec 2025 | Trial primary completion date: Jul 2032 ➔ Dec 2032

Trial completion date • Trial initiation date • Trial primary completion date • Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

Lubumbashi's medicinal plants against female infertility and the beneficial effects of Parinari curatellifolia Planch. Ex Benth., in the letrozole induced polycystic ovary syndrome in the female albino rats. (PubMed, J Ethnopharmacol) - "Various plant species have been identified as being used alone or combined to treat female infertility in Lubumbashi. The hydroethanolic extract of P. curatellifolia root bark shown the beneficial effects against PCOS correcting the related hormonal and metabolic disturbances, as well as neutralization of the free radicals."

Journal • Preclinical • Gynecology • Infertility • Metabolic Disorders • Polycystic Ovary Syndrome • Sexual Disorders

Novel benzoxazole-based hybrids as multi-target inhibitors of aromatase, EGFR, and PI3K with potential anti-breast cancer activity. (PubMed, Bioorg Med Chem) - "MTT assay showed that 6 and 9b were 4.5 and 2 times more potent than doxorubicin against MCF-7 cells, while 9a and 13b were 10 and 7.5 times more effective against MDA-MB-231 cells, respectively...Compound 13b exhibited comparable EGFRL858R inhibition to lapatinib and outperformed pictilisib against PI3Kα, PI3Kβ, and PI3Kδ. Compound 6 showed greater ARO inhibition than letrozole, while being slightly less potent than pictilisib against PI3Kα and PI3Kβ...Docking studies supported the in vitro enzymatic inhibition assays results. Thus, 9b and 13d are potent anti-breast cancer benzoxazoles with selective ARO and PI3kα inhibition activity, respectively, while 6, 9a, and 13b are multi-target inhibitors exhibiting other anticancer synergistic mechanisms."

Journal • Breast Cancer • Oncology • Solid Tumor • ANXA5 • BECN1 • CASP9 • EGFR • PIK3CA • PIK3CB • PIK3CD

Dalpiciclib plus endocrine therapy as adjuvant treatment for HR+/HER2- early breast cancer: updated results from the phase 3, DAWNA-A trial (SABCS 2025) - P3 | "Methods Women aged 18-75 yrs, with HR+/HER2-, node-positive, stage II-III BC were randomized (1:1) to receive Dalp (125 mg QD, 3-wk on/1-wk off, for 2 yrs) or placebo, both with ET (letrozole 2.5 mg, anastrozole 1 mg, or toremifene 60 mg QD, or tamoxifen 10 mg BID, for ≥5 yrs). Conclusions Addition of Dalp to adjuvant ET contiuned to show clinically meaningful improvement in IDFS within and beyond the 2-yr treatment period, with a manageable safety profile. These findings support the adjuvant use of Dalp for HR+/HER2- EBC."

Clinical • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2